MK-677 — also known as Ibutamoren — is a compound that fools the body into releasing more of its own growth hormone. It does this by copying ghrelin, the "hunger hormone" your stomach makes. The headline that sets it apart from the rest of its family: it is not an injection but an orally active small molecule — a once-daily pill — and it has genuine human trial data behind its effect on growth hormone.
In plain terms: a growth-hormone "nudge" you can swallow — with real human data on the hormones, and real caveats on the side effects.
What it is
MK-677 is a growth-hormone secretagogue. A secretagogue is simply something that makes a gland *secrete* (release) a hormone — here, the pituitary gland releasing growth hormone. It does not add growth hormone to the body directly; it presses the body's own "release" button.
Two things make it unusual:
- It is not a peptide injection. Most compounds that raise growth hormone this way — ipamorelin, the GHRPs, sermorelin — are peptides that break down in the gut and must be injected. MK-677 is a non-peptide small molecule that survives digestion, so it works as an oral tablet3.
- It acts like ghrelin. Ghrelin is the hormone that rises when you are hungry and, as a side job, triggers growth-hormone pulses6. MK-677 copies that action.
How it works
Ghrelin, discovered in 1999, is the body's natural key for a lock called the GHS-R1a receptor (the growth-hormone-secretagogue receptor) in the pituitary and hypothalamus6. MK-677 fits the same lock. When it switches that receptor on, the pituitary releases a pulse of growth hormone, and the liver responds by making more IGF-1 (insulin-like growth factor 1) — the downstream messenger that carries out much of growth hormone's work in muscle, bone, and other tissue2.
A key detail that vendor pages gloss over: because it copies a *hunger* hormone, appetite stimulation is not a bug — it is part of the same mechanism6.
In plain terms: it pulls the ghrelin lever. That lever raises growth hormone and IGF-1 — and, on the same pull, raises appetite.
Pharmacokinetics — why once a day
MK-677 is built to last long enough in the body that a single daily dose keeps IGF-1 elevated around the clock. Its plasma half-life — how long it takes for half a dose to clear — is reported at roughly 4 to 6 hours, but the growth-hormone/IGF-1 effect outlasts the drug itself, so trials used once-daily oral dosing and still saw a sustained rise in IGF-1 over months1. That is a very different rhythm from the short GHRP injections, which produce a quick pulse and clear within an hour.
MK-677 at a glance
| Property | MK-677 (Ibutamoren) |
|---|---|
| Type | Non-peptide small molecule (orally active) |
| Route studied | Oral tablet |
| Target | Ghrelin / GHS-R1a receptor |
| Main effect | Sustained rise in growth hormone and IGF-1 |
| Reported half-life | ~4-6 hours (effect on IGF-1 outlasts the drug) |
| Dosing rhythm in trials | Once daily |
| Regulatory status | Investigational; not approved |
What the trials actually found
MK-677 has something most research compounds lack: placebo-controlled human trials. The pattern across them is consistent and important — the compound reliably moves the *hormones*, but the *outcomes people care about* (strength, function, disease progression) did not follow. Note the model in each row:
| Study | Model | Key result | Year |
|---|---|---|---|
| Chapman et al.3 | Human (GH-deficient adults) | Oral MK-677 raised growth hormone and IGF-1 — proof the oral route engages the axis | 1997 |
| Murphy et al.2 | Human RCT (obese adults, 2 months) | Increased GH secretion, fat-free (lean) mass, and energy expenditure | 1998 |
| Nass et al.1 | Human RCT (n=65 healthy older adults, 1 year) | IGF-1 rose into the young-adult range; lean mass +~1.1 kg; but no gain in strength or function; appetite, edema and blood sugar rose | 2008 |
| Sevigny et al.4 | Human RCT (n=563, mild-moderate Alzheimer's, 1 year) | Raised IGF-1 (target engaged) but did not slow Alzheimer's progression | 2008 |
| Adunsky et al.5 | Human RCT (hip-fracture recovery, phase IIb) | No significant benefit on functional recovery | 2011 |
In plain terms: give it daily and the hormone numbers move in the "younger" direction, and lean mass ticks up1. But in the trials that asked "does that make people measurably stronger, sharper, or better-healed?", the answer kept coming back no145. That gap — real hormonal effect, unproven real-world benefit — is the single most honest thing to know about MK-677.
The honest limitations
Three signals recur across the human trials and deserve plain statement:
- Appetite. Because MK-677 copies a hunger hormone, increased appetite is expected and reported61. That is a feature for a cachexia (wasting) setting and a drawback otherwise.
- Fluid retention. Mild swelling (edema) and joint-related complaints are common with growth-hormone-raising agents and showed up in MK-677 trials1.
- Blood sugar and insulin sensitivity. MK-677 raised fasting blood glucose and reduced insulin sensitivity in the year-long older-adult trial — a metabolic trade-off that matters for anyone thinking about long-term use1.
And the overarching limit: it is not an approved medicine. It was developed as a drug candidate and studied seriously, but it never cleared approval, and its disease-focused trials failed. This page explains what it is and what the trials showed — not how to use it — and it takes no position on sourcing.
Latest research
- The 2008 older-adult trial (Nass et al.) remains the reference point: a full year of once-daily oral MK-677 in 65 healthy older adults restored IGF-1 toward youthful levels and added lean mass, but without measurable functional gain and with metabolic trade-offs1.
- The failed disease endpoints still define the honest ceiling: raising IGF-1 did not slow Alzheimer's disease4 or improve hip-fracture recovery5, a caution against assuming higher IGF-1 automatically means better outcomes.
- Newer interest is metabolic — MK-677 continues to appear in exploratory research on body composition and, more recently, fatty-liver disease, but no large trial has yet overturned the core picture. We update this section as results report.
The short version
MK-677 (Ibutamoren) is an oral ghrelin-mimetic that reliably raises growth hormone and IGF-1 and modestly increases lean mass in real human trials — a genuinely better-documented compound than most research peptides. But it is not approved, its Alzheimer's and hip-fracture trials failed, and human data flag increased appetite, fluid retention, and reduced insulin sensitivity. Educational overview only, not medical advice. For the injectable cousins, see GHRP-6 and GHRP-2.